Table 1.
Results of systematic review as to children and cardiovascular involvement
| Source | Study type | Country | Patients (n) | Age | Sex | Cardiovascular involvement | CV symptoms or signs | CV tests | Therapy (yes/no) type of therapy |
|---|---|---|---|---|---|---|---|---|---|
| • Cui et al. [5] | Case report | China | 1 | 55 days | F | Yes | Tachycardia | Troponin | i.v. sodium creatine phosphate and oxygen |
| • Sun et al. [6] | Retrospective study | China | 8 | 2 m–15y | 6M/2F | Yes (in 1M) | Heart failure coagulopathy | Non specific for CV disease | plasmapheresis and oxygen |
| • Xia et al. [9] | Retrospective study | China | 20 | 1d–14y7m | 13M/7F | No (CHD was a risk factor in 2/20) | Abnormal ECG | Procalcitonin | NA |
| • Zheng et al. [11] | Retrospective study | China | 25 | 3m–14y | 14M/11F | No (CHD was a risk factor in 2/25) | No | Cardiac enzymes | Antiretroviral agents, corticosteroids, i.v. immunoglobulin |
| • Li et al. [17] | Retrospective study | China | 102 (only 2 of them were children) | 4y | NA | No | No | Cardiac enzymes | NA |
| • Su et al. [18] | Retrospective study | China | 9 | 11m–9y9M | 3M/6F | Yes (in 6) | Fever (in 2) | Increase in cardiac enzymes | Symptomatic and respiratory support, inhaled interferon |
| • Dong et al. [24] | Retrospective study | China | 2135 | 0–18 y | 1208M/927F | Yes (in 13) | Myocardial injury, heart failure | NA | NA |
Abbreviations: CV cardiovascular, M males, F females, d days, m months, y years, CHD congenital heart disease, NA not available